Scrip Symbol / Code: NSE: RAINBOW, BSE: 543524
Date: May 23, 2026
Change in Director / Key Managerial Personnel
- The Board approved the re-appointment of Dr. Ramesh Kancharla (DIN: 00212270) as Chairman and Managing Director for a five-year term from August 11, 2026 to August 10, 2031, subject to shareholder approval at the ensuing AGM. He is liable to retire by rotation.
- The Board approved the re-appointment of Dr. Dinesh Kumar Chirla (DIN: 01395841) as Whole Time Director for a five-year term from August 11, 2026 to August 10, 2031, subject to shareholder approval at the ensuing AGM. He is liable to retire by rotation.
- The Board approved the re-appointment of Mr. Santanu Mukherjee as Independent Director for a second term of five years from October 22, 2026 to October 21, 2031, subject to shareholder approval.
- The Board approved the re-appointment of Ms. Sundari R. Pisupati as Independent Director for a second term of five years from September 16, 2026 to September 15, 2031, subject to shareholder approval.
- All four directors are confirmed to not be debarred from holding office by virtue of any SEBI Order or any other authority, and are not disqualified under Section 164 of the Companies Act, 2013.
- Dr. Ramesh Kancharla is the promoter of the company and father of Dr. Adarsh Kancharla, who is an Executive Director of the company.
- Dr. Dinesh Kumar Chirla has been associated with the Board since 2005 and has extensive experience in neonatology.
- Mr. Santanu Mukherjee is the former Managing Director of State Bank of Hyderabad with experience in banking finance and management.
- Ms. Sundari R. Pisupati is a qualified lawyer (India and New York) with over 32 years of experience in corporate and commercial law.
Key Financial or Operational Approvals
- The Board approved the audited standalone financial results for the quarter and financial year ended March 31, 2026.
- The Board approved the audited consolidated financial results for the quarter and financial year ended March 31, 2026.
- Statutory Auditors S.R. Batliboi & Associates LLP provided an unmodified opinion on the audited financial results (standalone and consolidated) for FY ended March 31, 2026.
- The Board recommended a final dividend of ₹3.5 per equity share (35%) on face value of ₹10 per share for FY ended March 31, 2026, subject to shareholder approval at the AGM.
- The dividend will be dispatched/credited within 30 days from the conclusion of the AGM.
- The Board re-appointed M/s. Lavanya & Associates LLP as Cost Auditors for the Financial Year 2026-27.
Strategic or Business Context
- No specific business outlook, risk commentary, or strategic updates were disclosed in this filing.
Any Other Material Information
- The 28th Annual General Meeting will be held on Wednesday, July 29, 2026 through Video Conferencing/Other Audio-Visual Means.
- The Board fixed Tuesday, July 21, 2026 as the Record Date for payment of final dividend (if approved) and for the AGM.
- All reappointments were based on recommendations of the Nomination and Remuneration Committee and Audit Committee.
- The Board meeting commenced at 4:45 PM and concluded at 6:30 PM on May 23, 2026.
- Detailed information is provided in Annexure-A (financial results and audit reports), Annexure-B (director reappointments), and Annexure-C (cost auditor appointment).